CSL to Begin Clinical Trials for Horizon 2 Immunoglobulin Manufacturing Process Following FDA and EMA Discussions
核心洞察
CSL (搜索) announced it will initiate clinical trials to support regulatory approval of its proprietary Horizon 2 technology, a new manufacturing process designed to increase immunoglobulin yield from plasma.
The studies will evaluate the safety and efficacy of immunoglobulin produced via Horizon 2, following discussions with both the U.S. FDA and the European Medicines Agency.
Clinical work is expected to commence in mid-2027 using material manufactured at CSL (搜索)'s Broadmeadows facility in Australia.
Australian biotechnology firm CSL (搜索) announced on Wednesday that it will commence clinical trials to support regulatory approval for a novel manufacturing process designed to increase immunoglobulin output from the same volume of plasma. The decision follows consultations with both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
The studies will evaluate the safety and efficacy of immunoglobulin produced using CSL (搜索)'s proprietary Horizon 2 technology. The company described Horizon 2 as a patented process that increases yield, potentially improving manufacturing efficiency for one of its key product lines.
Clinical work is expected to begin in mid-2027, utilizing material produced at CSL (搜索)'s Broadmeadows facility in Australia. The timeline positions the program for a significant step forward in the company's plasma-derived therapies portfolio.
The clinical trial announcement comes on the heels of CSL (搜索)'s November commitment to invest $1.5 billion in the United States to manufacture plasma-derived therapies, part of a broader strategy to expand its manufacturing footprint over the next five years.
Market response to the announcement was notably positive. Shares of the Melbourne-based company rose as much as 7.7% to A$128.670, reaching their highest level since April 29. The stock was the top gainer on the benchmark S&P/ASX 200 index, which itself was up 1.1% on the day.
Immunoglobulin therapies, derived from human plasma, are used to treat a range of conditions including primary immunodeficiency disorders, autoimmune diseases, and neurological conditions. Improving manufacturing yield from existing plasma supplies addresses a critical efficiency challenge in the production of these life-saving therapies.